Condition

Giant Cell Glioblastoma (3)

Gliosarcoma (3)

Small Cell Glioblastoma (3)

Glioblastoma (2)

Glioblastoma With Oligodendroglial Component (2)

Recurrent Glioblastoma (2)

Oligodendroglioma (1)

Relapsed Glioblastoma (1)

Overall Status

Completed (2)

Withdrawn (1)

Phase

phase 2 (2)

phase 3 (1)

Sponsor

Celldex Therapeutics (2)

Jonsson Comprehensive Cancer Center (1)

Collaborator

Brain Tumor Funders Collaborative (1)

Bristol-Myers Squibb (1)

Northwest Biotherapeutics (1)

Intervention

klh (2)

rindopepimut (cdx-110) with gm-csf (2)

autologous dendritic cells pulsed with tumor lysate antigen vaccine (1)

bevacizumab (1)

laboratory biomarker analysis (1)

nivolumab (1)

quality-of-life assessment (1)

questionnaire administration (1)

temozolomide (1)

Study Documents

Intervention Type

drug (2)

biological (1)

other (1)

Funder Type

Industry (2)

Other (1)

Study Type

Interventional (3)

small cell glioblastoma

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Giant Cell Glioblastoma, Gliosarcoma, Oligodendroglioma Trial in Los Angeles (autologous dendritic cells pulsed with tumor

Withdrawn

Giant Cell Glioblastoma
+4 more

autologous dendritic cells pulsed with tumor lysate antigen Vaccine
+4 more

Los Angeles, California

UCLA / Jonsson Comprehensive Cancer Center

Jul 22, 2020

Glioblastoma, Small Cell Glioblastoma, Giant Cell Glioblastoma Trial in United States (Bevacizumab, Rindopepimut (CDX-110) with

Completed

Glioblastoma
+6 more

Bevacizumab
+2 more

Birmingham, Alabama
+44 more

Feb 12, 2020

Glioblastoma, Small Cell Glioblastoma, Giant Cell Glioblastoma Trial in Worldwide (Rindopepimut (CDX-110) with GM-CSF,

Completed

Glioblastoma
+4 more

Rindopepimut (CDX-110) with GM-CSF
+2 more

Birmingham, Alabama
+222 more

Jan 11, 2018